Relmada Therapeutics, Inc.
Balance Sheet
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Equivalents | $11.3M | $9.8M | $3.5M | $1.4M | $1.4M | $1.1M | $3.9M | $1.5M |
| Accounts Receivable | — | — | — | — | — | — | — | — |
| Inventory | — | — | — | — | — | — | — | — |
| Total Current Assets | $219.0M | $235.3M | $94.0M | $14.9M | $21.1M | $27.7M | $45.8M | $55.7M |
| Property, Plant & Equipment | — | — | — | — | — | — | — | — |
| Goodwill | — | — | — | — | — | — | — | — |
| Intangible Assets (Excl. Goodwill) | — | — | — | — | — | — | — | — |
| Total Assets | $219.1M | $235.4M | $94.0M | $14.9M | $21.1M | $27.7M | $45.8M | $55.7M |
| Liabilities | ||||||||
| Accounts Payable | $2.4M | $5.7M | $1.6M | $1.5M | $1.4M | $1.3M | $4.1M | $2.3M |
| Total Current Liabilities | $7.4M | $12.9M | $6.4M | $5.2M | $5.1M | $5.2M | $10.3M | $8.1M |
| Long-Term Debt | — | — | — | — | — | — | — | — |
| Total Liabilities | $12.5M | $16.6M | $7.5M | $5.4M | $5.2M | $5.2M | $10.3M | $8.1M |
| Stockholders' Equity | ||||||||
| Retained Earnings | $-730.2M | $-717.3M | $-698.3M | $-678.4M | $-668.3M | $-658.4M | $-640.9M | $-622.2M |
| Total Stockholders' Equity | $206.6M | $218.7M | $86.5M | $9.5M | $15.9M | $22.4M | $35.5M | $47.6M |